- Oops!Something went wrong.Please try again later.
Boston, Massachusetts--(Newsfile Corp. - September 27, 2021) - Block & Leviton announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sava.
What is this all about?
On August 24, 2021, after market hours, Cassava Sciences stock dropped over 20% in response to a report raising concerns over the quality of the studies into the Company's experimental Alzheimer's drug simufilam. A letter posted on a government website urged the U.S. Food and Drug Administration's (FDA) center for drug evaluation and research to pause simufilam clinical trials.
On this news, Cassava's stock price plunged over 20%, in after hours trading on August 24, 2021.
Who is eligible?
Anyone who purchased Cassava stock between September 14, 2020 and August 27, 2021 is potentially eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What should you do next?
The deadline to seek appointment as lead plaintiff is October 26, 2021. A class has not yet been certified, and until a certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Why should you contact Block & Leviton?
Many law firms have issued releases about this matter; most of those firms do not actually litigate securities class actions. Block & Leviton is a law firm that actually litigates cases. We are dedicated to obtaining significant recoveries on behalf of defrauded investors through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email email@example.com with any questions.
This notice may constitute attorney advertising.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97736